Muhammet Cinar

Muhammet Cinar

Auto-generated profile, based on publicly available information

Muhammet Cinar

Division of Rheumatology, Department of Internal Medicine, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Türkiye

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2019 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
DSDilek Solmaz
Dilek Solmaz
SBSibel Bakirci
Sibel Bakirci
GKGezmis Kimyon
Gezmis Kimyon
EGEsen Kasapoglu Gunal
Esen Kasapoglu Gunal
ADAtalay Dogru
Atalay Dogru
SASibel Zehra Aydin
Sibel Zehra Aydin

20 July 2012 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
OKOmer Karadag
Omer Karadag
ATABDURRAHMAN TUFAN
ABDURRAHMAN TUFAN
VYVeli Yazisiz
Veli Yazisiz
KUKemal Ureten
Kemal Ureten
SYSedat YILMAZ
Sedat YILMAZ
ADAyhan Dinc
Ayhan Dinc

24 April 2018 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
SAServet Akar
Servet Akar
PCPınar Cetin
Pınar Cetin
UKUmut Kalyoncu
Umut Kalyoncu
OKOmer Karadag
Omer Karadag
ISIsmail Sari
Ismail Sari
FOFatos Onen
Fatos Onen

11 December 2014 in Rheumatology
Verified
Journal Article
Open access
PDF file
SYSedat YILMAZ
Sedat YILMAZ
MCMuhammet Cinar
Muhammet Cinar
ISIsmail Simsek
Ismail Simsek
HEHakan Erdem
Hakan Erdem
SPSalih Pay
Salih Pay
S ir , The leading causes of AA amyloidosis are mainly chronic inflammatory diseases such as RA and JIA, however, FMF is responsible for >60% of patients with AA amyloidosis in Turkey [ 1 , 2 ]. Although colchicine seems effective in the prevention of amyloidosis, no established treatment protocol exists for amyloidosis. There is evidence showing the effectiveness of some biologic treatments, including anti-TNF agents and IL-1 antagonists.

5 May 2020 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
ETEmre Tekgöz
Emre Tekgöz
SÇSeda Çolak
Seda Çolak
MÇMuhammet Çinar
Muhammet Çinar
SYSedat YILMAZ
Sedat YILMAZ
Background&Aim: Idiopathic granulomatous mastitis is a rare, benign inflammatory disease of breast. There is no general agreement on the appropriate treatment choice. The aim of the study was to investigate the immunosuppressive administer for idiopathic granulomatous mastitis and risk factors related with disease recurrence. The data of 53 patients with idiopathic granulomatous mastitis were evaluated for this cross-sectional retrospective study. Demographic features and clinical characteristics and course of the patients were obtained from file records. The mean age of the patients was 37.2 ± 6.6 years. Fifty-one of 53 patients received immunosuppressive treatment with or without surgery. Forty-seven (88.6%) of the patients received only immunosuppressive treatment without surgery, while 4 (7.54%) patients received immunosuppressive treatment after surgery. Forty-one (77.3%) of 47 patients who had no surgical resection received methotrexate as immunosuppressive treatment. Other 6 (11.3%) patients received azathioprine or corticosteroid treatment. Complete or partial remission was observed in 50 (98%) of 51 patients who received immunosuppressive treatment, while only 1 (2%) patient did not reach remission. No factors were found related with recurrence of disease. Methotrexate seems to be efficient in the treatment of idiopathic granulomatous mastitis and provides drug free remission.

5 January 2018 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
NBNazife Sule Yasar Bilge
Nazife Sule Yasar Bilge
ISIsmail Sari
Ismail Sari
DSDilek Solmaz
Dilek Solmaz
SSSoner Senel
Soner Senel
HEHakan Emmungil
Hakan Emmungil
TKTimucin Kasifoglu
Timucin Kasifoglu